CX3CL1 and neoplasm: To explore a possible prognostic impact of CX3CL1 in advanced ovarian cancer, a cohort of 219 HGSOC primary (ovarian) tumours (FIGO III and IV only) was immunohistochemically stained against CX3CL1 and semiquantitatively scored and confirmed by an experienced pathologist (KS) (Fig. 1A and Table S1).